Device/Diagnostics Quarterly Deal Statistics, Q2 2015
A look at financing, M&A and alliance activity April–June 2015
At $1.8 billion, Q2 device financing nearly doubled the Q1 total, mainly from an increase in IPOs and early VC rounds, and acquisitions were slightly higher at $4.7 billion. Diagnostics funding also increased to $784 million from Q1's $597 million, and Danaher's monster $13.8 billion buy of life sciences company Pall headlined the second quarter's $15.6 billion total in diagnostics M&A activity.
You may also be interested in...
Minimally invasive technologies are finding their way into the suites of ophthalmology surgeons. Just over the past six months, Allergan has acquired two pre-commercial medtech companies developing miniature implants to treat glaucoma and dry eye disease. Meanwhile, Glaukos, a leader in the micro-invasive glaucoma surgery market, remains one of the more successful medtech IPOs.
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
Glaukos held its first earnings call Aug. 12 following the completion of its $113 million IPO, which closed in June. The firm is the first to the U.S. market with a micro-invasive glaucoma surgery, or MIGS, device and it is working to get its next-generation system that can be performed separate from cataract surgery to market in the coming years.